Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
Latest Information Update: 05 Feb 2023
At a glance
- Drugs Pralsetinib (Primary)
- Indications Non-small cell lung cancer; Thyroid cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Blueprint Medicines
Most Recent Events
- 13 Feb 2020 According to a Blueprint Medicines Corporation, the company plans to Submit an NDA to the FDA for pralsetinib for the treatment of patients with MTC previously treated with an approved multi-kinase inhibitor in the second quarter of 2020.
- 23 Dec 2019 New trial record